Novo Nordisk, Sanofi Cap Feud Over Insulin Pen
Novo Nordisk A/S has resolved a dispute with Sanofi-Aventis SA over its insulin pen Solostar, a product Novo claimed infringed the patent for its top-selling insulin device FlexPen....To view the full article, register now.
Already a subscriber? Click here to view full article